AUSTIN, Texas--(BUSINESS WIRE)--Introgen Therapeutics, Inc. (NASDAQ:INGN), a biopharmaceutical company focused on the discovery, development and commercialization of targeted molecular therapies for the treatment of cancer and other diseases, today announced the appointment of Robert “Bob” Pearson to its board of directors. Mr. Pearson brings more than 20 years of management and product experience in the pharmaceutical industry.
